Krystal Biotech, Inc. (KRYS) Stock: Price, Forecast & Analyst Target
Krystal Biotech, Inc. (KRYS) — MoonshotScore 96/100 (Exceptional band), calculated Nov 18, 2026. Price $315.82 (+0.15%), as of the Nov 19, 2026 trading session; market cap $9.36B. Expected results Feb 16, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 10.26× (cash as of Sep 30, 2026) · expected results Feb 16, 2027
Krystal Biotech, Inc. · KRYS · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Krystal Biotech develops redosable gene therapies for severe orphan diseases, with B-VEC at the front of a broader dermatology and rare-disease pipeline. Reported economics no longer resemble a pre-revenue biotechnology developer: sales, profit, and operating cash flow are established, while liquidity continues to build. The case now rests on whether that revenue base can keep expanding without the expense base outrunning demand.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Krystal Biotech (KRYS)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.
- EPS beat 7 of the last 8 reports
- Altman Z 36.92 · Piotroski F 4
- ROE 17.5% · ROA 10.1% · current ratio 7.89
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 97 | Exceptional | |
| 97 | Exceptional | |
| 89 | Exceptional | |
| 89 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $315.82 | |
| Change on the day | +0.15% | |
| 52-week range | $202.99–$382.54 | |
| Market capitalisation | $9.36B | — |
| Price / earnings (trailing) | 38.98 | |
| Shares traded on the day | 295.9K | |
| Beta (volatility vs the S&P 500) | 0.5 |
Why Krystal Biotech scores 96
Share price, last 12 months +51.7%
$201.21 $305.23
What the price assumes
12.2% a year of free-cash-flow growth for ten years is what a $9.05B market value ( snapshot) asks for.
The growth the price implies sits inside what the business has recently delivered, so the valuation leans on that record continuing.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $310.08M. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 10 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 11.0% either way.
- +52.8%Feb ’24
- +0.4%May ’24
- -6.9%Aug ’24
- -1.1%Nov ’24
- +16.5%Feb ’25
- -15.7%May ’25
- -12.5%Aug ’25
- +2.9%Nov ’25
- +2.5%Feb ’26
- +7.0%May ’26
- -4.8%Aug ’26
- -8.2%Nov ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | -8.2% | -8.8% | |
| Beat | Miss | -4.8% | -2.8% | |
| Beat | Beat | +7.0% | +17.6% | |
| Beat | Beat | +2.5% | -3.5% | |
| Beat | Miss | +2.9% | +1.0% | |
| Beat | In line | -12.5% | -12.4% | |
| Miss | Miss | -15.7% | -17.1% | |
| Beat | In line | +16.5% | +12.6% | |
| Beat | Miss | -1.1% | +11.0% | |
| Beat | Beat | -6.9% | -3.9% | |
| Miss | Miss | +0.4% | -3.9% | |
| Beat | Beat | +52.8% | +43.7% |
Misses cost real money here: the average first-session move after a miss was -7.6%.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “additional patients”, “academic sites” — none of them came up in Q2 FY2026.
- Gone quiet: “patient-reported outcome”, “before year-end”, “global filing”, “hailey-hailey disease” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” fell from 2.9 to 0.5 per 1,000 words, and confident words such as “record” and “strong” fell from 3.5 to 1.7.
Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.
Our track record on this stock
Since the score went from 99 to 96 while the share price moved -7.6% through .
The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 100% of 18 rate it a buy; the average target sits +32.5% from the price of $315.82.
- Last 90 days: 5 rating actions, every one a reaffirmation.
- Our signals: Exceptional band; strongest pillar Financial Safety (96), weakest Valuation (40).
Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Based on this enrollment timeline, we now anticipate interim study results in the first half of 27.
Suma Krishnan · Statement from
With continued investment and expansion of our trial network, we now expect to complete the enrollment and report top-line results in 2027.
Suma Krishnan · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Krystal Biotech (KRYS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Krystal Biotech (KRYS), and what does it report?
Short answer · as of
Krystal is a gene-therapy developer built around treatments that can be administered repeatedly rather than a diversified drug manufacturer.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Its programs span severe inherited skin disorders, cystic fibrosis, and aesthetic dermatology, with B-VEC identified as the most advanced candidate. The economic task is to translate those programs into patient treatment; clinical progress by itself is not revenue.
What do the latest results show for Krystal Biotech (KRYS)?
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Revenue advanced again in the latest reported period, while gross profit kept pace. Research spending and selling, general, and administrative expense each eased from the preceding period, allowing operating profit to rise even as net profit declined modestly. The immediate mechanism was operating leverage within the reported cost base, not a reduction in gross profitability.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $127.34M Sep 30, 2026
- Latest quarter · R&D
- $14.89M Sep 30, 2026
- Latest quarter · SG&A
- $33.75M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $71.14M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $127.34M | $14.89M | $33.75M | $71.14M |
| Jun 30, 2026 | $119.22M | $14.52M | $39.85M | $58.42M |
| Mar 31, 2026 | $116.36M | $15.33M | $41.01M | $53.69M |
| Dec 31, 2025 | $107.11M | $16.20M | $41.28M | $44.44M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $127.34M Nov 2, 2026
- Latest report · revenue estimate
- $125.77M Nov 2, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 2, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 2, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 2, 2026 | $127.34M | $125.77M | $2.0500 | $1.7900 |
| Aug 3, 2026 | $119.22M | $120.93M | $1.7900 | $1.7000 |
| May 4, 2026 | $116.36M | $112.11M | $1.8300 | $1.4500 |
| Feb 17, 2026 | $107.11M | $105.35M | $1.7000 | $1.6200 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $127M | $63M | $2.05 (diluted) |
| Jun 2026 | $119M | $55M | $1.79 (diluted) |
| Mar 2026 | $116M | $56M | $1.83 (diluted) |
| Dec 2025 | $107M | $51M | $1.70 (diluted) |
What are the financial strengths and risks for Krystal Biotech (KRYS)?
Short answer
Cash and short-term investments were $911.85M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $91.25M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Krystal carries substantial cash and short-term investments, an additional pool of long-term investments, and little debt. Positive operating cash flow throughout the displayed run, paired with comparatively modest capital spending, has allowed liquid resources to rise while the company continues funding research and commercial overhead.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $91.25M Sep 30, 2026
- Previous quarter · operating cash flow
- $74.79M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $91.25M | −$1.00M |
| Jun 30, 2026 | $74.79M | −$3.56M |
| Mar 31, 2026 | $80.38M | −$7.15M |
| Dec 31, 2025 | $77.51M | −$2.14M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Krystal Biotech (KRYS)?
Short answer · as of
The next earnings report is expected on Feb 16, 2027. The number it tests is the $7.67 EPS analysts carry for it.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Krystal’s scheduled earnings release puts revenue continuity, operating leverage, and cash conversion in focus. Useful confirmation would be another advance in revenue accompanied by resilient gross profit, controlled operating expenses, positive operating cash flow, and further preservation of liquidity.
What management is planning
How does Krystal Biotech compare with its peers?
Short answer
Krystal Biotech's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Development-stage rare-disease companies commonly depend on external capital while awaiting commercial validation; Krystal already reports recurring revenue, operating profit, net income, and positive operating cash flow. Yet its strategic identity remains that of a focused redosable gene-therapy platform rather than a diversified commercial biopharma business. That combination makes present earnings quality and candidate progression equally relevant comparisons.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $65.83 Nov 19, 2026 | $16.1B | 98 5-pillar Nov 18, 2026 | |
| Krystal Biotech (KRYS) — this page | $315.82 | $9.36B | 96 |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $72.70 Nov 19, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $361.00 – $474.00
- Consensus target
- $418.40
- Median target
- $416.00
- Revenue estimate
- $497.50M
- EPS estimate
- $7.67
Consensus record · Captured .
Measured against a quoted price of $315.82 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 74
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 58
- Other transactions
- 16
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 465 Period end Sep 30, 2026
- Previous quarter · holders
- 443 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 4,439,770 |
| Blackrock, INC. | 3,590,630 |
| Avoro Capital Advisors LLC | 2,888,888 |
| State Street Corp | 1,420,127 |
| Vanguard Portfolio Management LLC | 1,286,854 |
Tracked investors
Which of the 16 named investors we follow held KRYS in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.14% | $33.23M | Added +83.4% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Krystal Biotech (KRYS)?
Krystal Biotech Healthcare Stock: Key Questions Answered
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is B-VEC’s role in Krystal Biotech’s business?
B-VEC is Krystal’s most advanced therapeutic candidate and the clearest program-level test of its redosable gene-therapy approach. The remaining pipeline extends that platform across inherited skin disease, cystic fibrosis, and aesthetic dermatology.
Is Krystal Biotech still a clinical-stage biotechnology company?
Clinical development remains central to Krystal’s identity, but its financial profile is no longer pre-revenue. The company now reports substantial revenue, operating profit, net income, and positive operating cash flow alongside continued research spending.
Can Krystal fund its redosable gene-therapy pipeline internally?
Current operations are generating cash while liquid resources and investments comfortably exceed debt. That combination gives Krystal room to fund research without relying on balance-sheet depletion at the recent operating pace.
What do recent KRYS insider transactions show?
Recent recorded activity was dominated by sales and other transfers, with no purchases recorded. The pattern offers no affirmative buying signal, although the transactions alone do not establish why insiders sold.
What is the KRYS stock price today?
The last price recorded for Krystal Biotech, Inc. (KRYS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the KRYS price target?
The analyst consensus price target for Krystal Biotech, Inc. (KRYS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 80 figures on this page — 2 from SEC filings and earnings calls, 68 from Financial Modeling Prep (FMP), 6 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold KRYS
Funds in our ETF coverage that list KRYS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Russell 2000 ETF (IWM) | 0.30% |
